Skip to main content

Table 5 Joint effect of autoimmune disease and DMARD or prednisone use on 30-day mortality

From: The association between autoimmune disease and 30-day mortality among sepsis ICU patients: a cohort study

Association between autoimmune disease and 30-day mortality, accounting for chronic DMARD and prednisone use Sepsis cohort Septic shock cohort
OR (95% CI) P value OR (95% CI) P value
All potential confounders adjusteda
 No autoimmune disease presence
  No chronic DMARD/prednisone usage 1.00 Reference 1.00 Reference
 Autoimmune disease presence
  No chronic DMARD or prednisone usage 0.82 (0.58–1.16) 0.272 0.76 (0.50–1.14) 0.186
  Chronic DMARD or prednisone usage 0.89 (0.65–1.20) 0.452 0.87 (0.62–1.22) 0.428
SOFA score adjusted
 No autoimmune disease presence
  No chronic DMARD/prednisone usage 1.00 Reference 1.00 Reference
 Autoimmune disease presence
  No chronic DMARD or prednisone usage 0.80 (0.57–1.11) 0.190 0.73 (0.49–1.07) 0.114
  Chronic DMARD or prednisone usage 0.84 (0.62–1.12) 0.231 0.77 (0.55–1.07) 0.121
  1. Sepsis cohort—ICU patients with sepsis as defined by Martin criteria. Septic shock cohort—ICU patients with sepsis as defined by Martin criteria and three consecutive mean arterial blood pressure readings below 65 mmHg in a 30-min period or at least one dose of vasopressors during the ICU stay
  2. OR odds ratio, CI confidence interval, DMARD disease-modifying antirheumatic drug, SOFA Sequential Organ Failure Assessment
  3. aOR adjusted for age, sex, race, SOFA score at ICU admission, Elixhauser comorbidity index, pre-admission chronic DMARD or prednisone use, ICU care unit, documented bacteremia, and infection site